keyword
MENU ▼
Read by QxMD icon Read
search

Pancreatic neuroendocrine

keyword
https://www.readbyqxmd.com/read/29451738/well-differentiated-grade-3-pancreatic-neuroendocrine-tumors-compared-with-related-neoplasms-a-morphologic-study
#1
Carlie S Sigel, Vitor Werneck Krauss Silva, Michelle D Reid, David Chhieng, Olca Basturk, Keith M Sigel, Tanisha D Daniel, David S Klimstra, Laura H Tang
BACKGROUND: Pancreatic neuroendocrine neoplasms with a Ki-67 labeling index greater than 20% were reclassified in 2017 by the World Health Organization into well differentiated (WD) and poorly differentiated grade 3 neuroendocrine carcinoma (NEC). The authors describe the cytologic features of grade 3 WD pancreatic neuroendocrine neoplasms compared with grade 2 neoplasms and NEC. METHODS: Fine-needle aspirates from 65 pancreatic neuroendocrine neoplasms were reviewed, and their cytomorphologic features were compared across grade 2, WD grade 3, and PD small cell type (PD-S), large cell type (PD-L), and type not otherwise specified (PD-NOS) neoplasms...
February 16, 2018: Cancer Cytopathology
https://www.readbyqxmd.com/read/29449689/current-and-emerging-therapies-for-pnets-in-patients-with-or-without-men1
#2
REVIEW
Morten Frost, Kate E Lines, Rajesh V Thakker
Pancreatic neuroendocrine tumours (PNETs) might occur as a non-familial isolated endocrinopathy or as part of a complex hereditary syndrome, such as multiple endocrine neoplasia type 1 (MEN1). MEN1 is an autosomal dominant disorder characterized by the combined occurrence of PNETs with tumours of the parathyroids and anterior pituitary. Treatments for primary PNETs include surgery. Treatments for non-resectable PNETs and metastases include biotherapy (for example, somatostatin analogues, inhibitors of receptors and monoclonal antibodies), chemotherapy and radiological therapy...
February 16, 2018: Nature Reviews. Endocrinology
https://www.readbyqxmd.com/read/29449151/multiphase-evaluation-of-contrast-enhanced-endoscopic-ultrasonography-in-the-diagnosis-of-pancreatic-solid-lesions
#3
Takuya Ishikawa, Yoshiki Hirooka, Hiroki Kawashima, Eizaburo Ohno, Kiyotaka Hashizume, Kohei Funasaka, Masanao Nakamura, Ryoji Miyahara, Osamu Watanabe, Masatoshi Ishigami, Hidemi Goto
BACKGROUND/OBJECTIVES: Time-intensity curve (TIC) under contrast-enhanced EUS (CE-EUS) allows continuous and quantitative evaluation of targeted area in the pancreas. However, TIC is not always available and the procedure is complicated. We aimed to propose a simplified method by evaluating multiple phases of CE-EUS in the diagnosis of pancreatic solid lesions. METHODS: We retrospectively reviewed 210 patients with pancreatic solid lesions including 142 with pancreatic ductal cancer (PDAC), 31 with pancreatic neuroendocrine neoplasm, 13 with solid pseudopapillary neoplasm and 24 with mass-forming pancreatitis who underwent CE-EUS and achieved final diagnoses...
February 9, 2018: Pancreatology: Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]
https://www.readbyqxmd.com/read/29448303/nomogram-predicting-the-risk-of-recurrence-after-curative-intent-resection-of-primary-non-metastatic-gastrointestinal-neuroendocrine-tumors-an-analysis-of-the-u-s-neuroendocrine-tumor-study-group
#4
Katiuscha Merath, Fabio Bagante, Eliza W Beal, Alexandra G Lopez-Aguiar, George Poultsides, Eleftherios Makris, Flavio Rocha, Zaheer Kanji, Sharon Weber, Alexander Fisher, Ryan Fields, Bradley A Krasnick, Kamran Idrees, Paula M Smith, Cliff Cho, Megan Beems, Carl R Schmidt, Mary Dillhoff, Shishir K Maithel, Timothy M Pawlik
BACKGROUND: The risk of recurrence after resection of non-metastatic gastro-entero-pancreatic neuroendocrine tumors (GEP-NET) is poorly defined. We developed/validated a nomogram to predict risk of recurrence after curative-intent resection. METHODS: A training set to develop the nomogram and test set for validation were identified. The predictive ability of the nomogram was assessed using c-indices. RESULTS: Among 1477 patients, 673 (46%) were included in the training set and 804 (54%) in y the test set...
February 15, 2018: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29444910/the-neuroendocrine-phenotype-genomic-profile-and-therapeutic-sensitivity-of-gepnet-cell-lines
#5
Tobias Hofving, Yvonne Arvidsson, Bilal Almobarak, Linda Inge, Roswitha Pfragner, Marta Persson, Göran Stenman, Erik Kristiansson, Viktor Johanson, Ola Nilsson
Experimental models of neuroendocrine tumour disease are scarce, and no comprehensive characterisation of existing gastroenteropancreatic neuroendocrine tumour (GEPNET) cell lines has been reported. In this study, we aimed to define the molecular characteristics and therapeutic sensitivity of these cell lines. We therefore performed immunophenotyping, copy number profiling, whole-exome sequencing and a large-scale inhibitor screening of seven GEPNET cell lines. Four cell lines, GOT1, P-STS, BON-1 and QGP-1, displayed a neuroendocrine phenotype while three others, KRJ-I, L-STS and H-STS, did not...
March 2018: Endocrine-related Cancer
https://www.readbyqxmd.com/read/29435419/two-nonsense-somatic-mutations-in-men1-identified-in-sporadic-insulinomas
#6
Cheng Qi, Jiayue Duan, Qingfeng Shi, Mingguang Wang, Changqing Yan
Insulinomas are functional pancreatic neuroendocrine tumors that cause hypoglycemia and severe morbidity. The aim of our study was to identify gene mutations responsible for tumorigenesis of sporadic insulinoma. Whole exome sequencing analysis was performed on tumors and paired peripheral blood from three patients with insulinomas. After initial analysis, somatic mutations were obtained and a deleterious protein product was further predicted by various bioinformatic programs. Whole exome sequencing identified 55 rare somatic mutations among three insulinoma patients, including MEN1 gene nonsense mutations (c...
February 2018: FEBS Open Bio
https://www.readbyqxmd.com/read/29435031/analysis-of-radiation-effects-in-two-irradiated-tumor-spheroid-models
#7
Afkar Al-Ramadan, Anja C Mortensen, Jörgen Carlsson, Marika V Nestor
Multicellular spheroids have proven suitable as three-dimensional in vivo-like models of non-vascularized micrometastases. Unlike monolayer-based models, spheroids mirror the cellular milieu and the pathophysiological gradients inside tumor nodules. However, there is limited knowledge of the radiation effects at the molecular level in spheroids of human origin. The present study is a presentation of selected cell biological processes that may easily be analyzed with methods available at routine pathology laboratories...
March 2018: Oncology Letters
https://www.readbyqxmd.com/read/29434915/immunohistochemical-cd73-expression-status-in-gastrointestinal-neuroendocrine-neoplasms-a-retrospective-study-of-136-patients
#8
Kohei Ono, Eisuke Shiozawa, Nobuyuki Ohike, Tomonori Fujii, Hideki Shibata, Tetsuya Kitajima, Koichiro Fujimasa, Naoko Okamoto, Yukiko Kawaguchi, Tasuku Nagumo, Sakiko Tazawa, Mayumi Homma, Toshiko Yamochi-Onizuka, Tomoko Norose, Hitoshi Yoshida, Masahiko Murakami, Gensyu Tate, Masafumi Takimoto
The WHO 2010 classification divides gastrointestinal neuroendocrine neoplasms (GI-NENs) into neuroendocrine tumor (NET) G1, NET G2, neuroendocrine carcinoma (NEC) and mixed adenoendocrine carcinoma (MANEC) groups. A total of 136 cases of GI-NENs diagnosed at our hospitals as gastrointestinal carcinoids, endocrine cell carcinomas and NENs over the last 11 years, using the WHO 2010 classification were assessed. Among the 136 cases, 88.2% (120/136) were classified into the NET group (NET G1/G2) and 11.8% (16/136) were classified into the NEC group (NEC/MANEC)...
February 2018: Oncology Letters
https://www.readbyqxmd.com/read/29433805/proactive-multi-modality-treatment-of-pancreatic-neuroendocrine-tumours-pnets-potential-survival-benefits
#9
L Tanno, D Mayo, S Mills, A Takhar, J Cave, L Nolan, B Stedman, F X Sundram, M Abu Hilal, H Connor, N Pearce, T Armstrong
BACKGROUND/OBJECTIVES: Primary and metastatic pancreatic neuroendocrine tumours (PNET) can be treated with combination of surgery, locoregional and systemic therapy. Survival benefits from individual treatments have been well reported, however, the combined outcome from multimodal treatments are not well described in the literature. We report outcomes in a cohort of PNET patients treated with proactive, multimodality therapy. METHODS: 106 patients were identified from a single tertiary referral centre prospective database...
December 14, 2017: Pancreatology: Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]
https://www.readbyqxmd.com/read/29430219/disease-control-on-lanreotide-autogel%C3%A2-120-mg-in-a-patient-with-metastatic-gastrinoma-a-case-report
#10
Maridi Aerts, Hendrik Reynaert
Gastrinomas are functionally active pancreatic neuroendocrine tumors (NETs) secreting gastrin and are associated with local or regional metastases in 60% of the cases. Somatostatin analogs (SSAs) are currently recommended as a first-line treatment for the symptomatic treatment of NETs. Although antiproliferative activity of SSAs has been demonstrated in various cancer types in several in vivo and in vitro studies, clinical benefits with SSAs have been only achieved in a small proportion of patients. We report a disease control on a long-acting SSA lanreotide in a patient with metastatic gastrinoma...
September 2017: Case Reports in Gastroenterology
https://www.readbyqxmd.com/read/29422353/editorial-peptide-receptor-radionuclide-therapy-as-neoadjuvant-therapy-for-resectable-or-potentially-resectable-pancreatic-neuroendocrine-neoplasms
#11
EDITORIAL
https://www.readbyqxmd.com/read/29421918/reply-cystic-pancreatic-neuroendocrine-tumors-a-diagnostic-challenge
#12
Javier A Cienfuegos, Luis Hurtado-Pardo, Javier Antoñanzas
We are grateful for the helpful comments of Varas et al. with regard to the phenotype of cystic pancreatic neuroendocrine tumors (CPNT) reported in a recent meta-analysis of 436 patients. Varas et al. highlight the lower incidence of CPNT diagnosed incidentally in 135 patients (44.6%) in comparison with a recent series of 49 patients with an incidental tumor diagnosis of 56.5%.
February 9, 2018: Revista Española de Enfermedades Digestivas
https://www.readbyqxmd.com/read/29419911/normoglycemic-glucagonoma-syndrome-associated-with-necrolytic-migratory-erythema
#13
R Feldmann, S Wahl, A Steiner
Glucagonoma is an extremely rare tumor of the pancreatic alpha-cells. Its estimated annual incidence is 1 case per 20 million individuals. Necrolytic migratory erythema (NME) is the hallmark clinical sign. We report a patient with normoglycemic glucagonoma and NME. A 44-year-old male patient presented with a 4-year history of unexplained exanthema and unintentional weight loss. Skin examination revealed a mildly pruritic rash on the trunc, the extremities and the face (fig 1). One found erythematous polycyclic migratory lesions with scaling and crusting margins and central resolution...
February 8, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29416715/long-term-follow-up-and-novel-splice-donor-mutation-in-men1-in-a-chinese-family
#14
Minghao Li, Qianqian Liu, Peihua Liu, Xiaoping Yi, Xiao Guan, Anze Yu, Longfei Liu, Feizhou Zhu
Heterozygous germline mutation of the MEN1 tumor suppressor gene is responsible for multiple endocrine neoplasia type 1. Parathyroid and thoracic neuroendocrine tumor specimens and DNA from two Han Chinese MEN1 family patients were analyzed using whole exome and Sanger sequencing. The proband (II-3) was sequentially diagnosed with pituitary adenoma, pancreatic tumor, adrenal cortical tumor, abdominal lipoma, and parathyroid adenoma during the 6-year follow-up. The son of the proband (III-6) was also diagnosed with a thoracic neuroendocrine tumor and a parathyroid adenoma during this period...
January 5, 2018: Oncotarget
https://www.readbyqxmd.com/read/29410677/development-of-a-method-to-implement-whole-genome-bisulfite-sequencing-of-cfdna-from-cancer-patients-and-a-mouse-tumor-model
#15
Elaine C Maggi, Silvia Gravina, Haiying Cheng, Bilal Piperdi, Ziqiang Yuan, Xiao Dong, Steven K Libutti, Jan Vijg, Cristina Montagna
The goal of this study was to develop a method for whole genome cell-free DNA (cfDNA) methylation analysis in humans and mice with the ultimate goal to facilitate the identification of tumor derived DNA methylation changes in the blood. Plasma or serum from patients with pancreatic neuroendocrine tumors or lung cancer, and plasma from a murine model of pancreatic adenocarcinoma was used to develop a protocol for cfDNA isolation, library preparation and whole-genome bisulfite sequencing of ultra low quantities of cfDNA, including tumor-specific DNA...
2018: Frontiers in Genetics
https://www.readbyqxmd.com/read/29404984/intrapancreatic-accessory-spleen-masquerading-as-a-pancreatic-neuroendocrine-tumor
#16
Kevin J Chan, Douglas Fenton-Lee
No abstract text is available yet for this article.
February 5, 2018: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
https://www.readbyqxmd.com/read/29401168/long-term-outcomes-of-gastroenteropancreatic-neuroendocrine-tumors
#17
Weiwei Chi, Richard R P Warner, David L Chan, Simron Singh, Eva Segelov, Jonathan Strosberg, Juan Wisnivesky, Michelle K Kim
OBJECTIVES: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare but have been increasing in incidence. Limited data on the long-term outcomes of patients with these tumors are available. METHODS: In this study, we used population-based data from the National Cancer Institute to assess long-term disease-specific survival (DSS) of patients who have undergone surgery for nonmetastatic disease. All patients with NETs of the stomach, small intestine, colon, rectum, appendix, and pancreas diagnosed between 1988 and 2009 were identified from the Surveillance, Epidemiology and End Results registry...
February 2, 2018: Pancreas
https://www.readbyqxmd.com/read/29399966/morphologically-invisible-proinsulin-secreting-adenoma-detected-by-ga-68-exendin-4-glp-1-receptor-positron-emission-tomography-ct
#18
Christoph Werner, Amelie Lupp, Robert Drescher, Martin Freesmeyer, Masoud Mireskandari, Christian Stoykow, Astrid Bauschke, Ulrich A Müller
This case report of a young man suffering from recurring hypoglycaemia illustrates a rare condition of a neuroendocrine tumour, predominantly secreting proinsulin and invisible to conventional imaging approaches. Only a GLP-1 receptor PET/CT using Exendin-4 visualized the pancreatic lesion and enabled curative therapy, confirming the diagnostic value of this tracer for detection of neuroendocrine tumours. As only few publications on this topic are available, an overview of the available data is also given. The known cut-off value of 60% for proinsulin level indicating malignancy is critically discussed...
February 5, 2018: Journal of Medical Imaging and Radiation Oncology
https://www.readbyqxmd.com/read/29398971/incidental-detection-of-asymptomatic-brain-metastases-on-18f-fluoride-positron-emission-tomography-computed-tomography-and-68ga-dotanoc-positron-emission-tomography-computed-tomography-in-a-patient-with-concomitant-breast-carcinoma-and-a-pancreatic-neuroendocrine
#19
Ruth Brown, Phei Shan Chuah, Emmanouil Panagiotidis, Sobhan Vinjamuri
A 54-year-old female treated for locally advanced ductal breast carcinoma was also diagnosed with a pancreatic neuroendocrine tumour. A staging 68Ga DOTANOC positron emission tomography/computed tomography (PET/CT) demonstrated somatostatin receptor-positive foci within the brain parenchyma. A whole body 18F-fluoride PET/CT also demonstrated several foci of low-grade tracer uptake in the brain. Magnetic resonance imaging confirmed several cerebral and cerebellar metastases. This case highlights the need to be aware of each tumor's metastatic profile and the careful attention required for thoroughly evaluating imaging in the presence of multiple pathologies...
January 2018: World Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/29397338/preoperative-imaging-and-pathologic-classification-for-pancreatic-neuroendocrine-tumors
#20
S Deguelte, L de Mestier, O Hentic, J Cros, R Lebtahi, P Hammel, R Kianmanesh
The management of patients with pancreatic neuroendocrine tumor (PNET), whether hormonally secretory or not, is multidisciplinary and often multimodal. Surgical treatment plays a central role because complete resection is the only potentially curative treatment. The choice of the therapeutic plan for a PNET requires precise localization of the primary tumor (which may sometimes be multiple in case of genetic predisposition), confirmation of the diagnosis of PNET, a search for metastases (mainly hepatic), and identification of the main histoprognostic factors...
January 31, 2018: Journal of Visceral Surgery
keyword
keyword
5478
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"